Evidence map›Paper›PMID 42870211›Full record

ArticleJournal of natural medicines2026

Antiproliferative activities of panduratin A and its derivatives against U-251 MG glioblastoma cells and U-251 MG cancer stem-like cells: structure-activity relationships and identification of PHB2 as a candidate binding protein.

Kousuke Araki, Yuna Yoshitani, Rina Okamoto, Shigekuni Hosogi, Ryota Fujikawa, Moe Kaneko, Reia Ishikura, Chiho Shimadzu, Yuzuki Takahashi, Rina Mantani and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of natural medicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Kousuke ArakiLaboratory of Pharmacognosy, Kyoto Pharmaceutical University, 1, Misasagi-Shichono-cho, Yamashina-ku, Kyoto-shi, Kyoto, 607-8412, Japan.ORCID http://orcid.org/0009-0000-6166-2452
Yuna YoshitaniLaboratory of Pharmacognosy, Kyoto Pharmaceutical University, 1, Misasagi-Shichono-cho, Yamashina-ku, Kyoto-shi, Kyoto, 607-8412, Japan.
Rina OkamotoLaboratory of Pharmacognosy, Kyoto Pharmaceutical University, 1, Misasagi-Shichono-cho, Yamashina-ku, Kyoto-shi, Kyoto, 607-8412, Japan.
Shigekuni HosogiLaboratory of Clinical and Translational Physiology, Kyoto Pharmaceutical University, 5, Misasagi-Nakauchi-cho, Yamashina-ku, Kyoto-shi, Kyoto, 607-8414, Japan.
Ryota FujikawaLaboratory of Pharmacognosy, Kyoto Pharmaceutical University, 1, Misasagi-Shichono-cho, Yamashina-ku, Kyoto-shi, Kyoto, 607-8412, Japan.
Moe KanekoLaboratory of Pharmacognosy, Kyoto Pharmaceutical University, 1, Misasagi-Shichono-cho, Yamashina-ku, Kyoto-shi, Kyoto, 607-8412, Japan.
Reia IshikuraLaboratory of Pharmacognosy, Kyoto Pharmaceutical University, 1, Misasagi-Shichono-cho, Yamashina-ku, Kyoto-shi, Kyoto, 607-8412, Japan.
Chiho ShimadzuLaboratory of Pharmacognosy, Kyoto Pharmaceutical University, 1, Misasagi-Shichono-cho, Yamashina-ku, Kyoto-shi, Kyoto, 607-8412, Japan.
Yuzuki TakahashiLaboratory of Pharmacognosy, Kyoto Pharmaceutical University, 1, Misasagi-Shichono-cho, Yamashina-ku, Kyoto-shi, Kyoto, 607-8412, Japan.
Rina MantaniLaboratory of Pharmacognosy, Kyoto Pharmaceutical University, 1, Misasagi-Shichono-cho, Yamashina-ku, Kyoto-shi, Kyoto, 607-8412, Japan.
Tomoe OhtaLaboratory of Pharmacognosy, Kyoto Pharmaceutical University, 1, Misasagi-Shichono-cho, Yamashina-ku, Kyoto-shi, Kyoto, 607-8412, Japan.ORCID http://orcid.org/0000-0002-4698-651X
Seikou NakamuraLaboratory of Pharmacognosy, Kyoto Pharmaceutical University, 1, Misasagi-Shichono-cho, Yamashina-ku, Kyoto-shi, Kyoto, 607-8412, Japan. naka@mb.kyoto-phu.ac.jp.ORCID http://orcid.org/0000-0003-3172-299X

Funding

Japan Society for the Promotion of Science 23H02642Japan Society for the Promotion of Science 25K10040
6 · The paper itself

Abstract

Panduratin A (1), a cyclohexenyl chalcone isolated from Boesenbergia rotunda, has been reported to exhibit various biological activities, including antitumor effects. However, its antiproliferative activity against glioblastoma cells and glioblastoma-derived cancer stem-like cells (CSCs), and the molecular basis of this activity, remain incompletely elucidated. In this study, we evaluated the antiproliferative activity of 1 against U-251 MG glioblastoma cells (non-CSCs) and U-251 MG CSCs and found that 1 exhibited potent activity against both cell populations. To investigate the structural features associated with this activity, cyclohexenyl chalcone derivatives of 1 (2-11) were synthesized through a chalcone intermediate generated from an acetophenone precursor, followed by Diels-Alder reactions with dienes. Structure-activity relationship analysis, particularly in U-251 MG non-CSCs, suggested that the phenolic oxygen functionalities of 1 contribute to its potent activity, whereas some acetylated derivatives retained moderate activity. Based on this observation, affinity-based target identification using U-251 MG non-CSC extracts identified prohibitin 2 (PHB2), an inner mitochondrial membrane protein, as a candidate binding protein for 1. In these cells, 1 also markedly altered the mitochondrial morphology and reduced the mitochondrial membrane potential. Together, these findings suggest that the antiproliferative activity of 1 in U-251 MG glioblastoma cells may be associated with PHB2 and mitochondrial alterations.

Indexed as

Cancer stem cellsCyclohexenyl chalconeGlioblastomaPanduratin AProhibitin 2Structure–activity relationship

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.